Treatment

Izalontamab Brengitecan clinical trials

1 indexed studies · 1 currently recruiting

RecruitingPHASE2
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
This study is for people with advanced non-small cell lung cancer that has a specific genetic change (homozygous MTAP deletion) and has progressed after previous treatments. It aims to see how safe and effective a new medicine called Navlimetostat (BMS-986504) is in these patients.
For: Carcinoma, Non-Small-Cell Lung
United States · Australia · China